Login to Your Account

Mitsubishi Tanabe to buy Neuroderm for $1.1 billion

By Michael Fitzhugh
Staff Writer

Monday, July 24, 2017

Mitsubishi Tanabe Pharma Corp. is buying Israel-based Neuroderm Ltd., the developer of a belt-worn pump for the continuous delivery of liquid levodopa/carbidopa to treat severe Parkinson's disease, for $1.1 billion in cash, or $39 per share.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription